ERBB2 and ovarian cancer: In pre-clinical studies, Sun and colleagues showed that HER2-CAR-T-cells were able to recognize and kill HER2+ ovarian cancer cells [160], advancing this therapeutic approach for the treatment of HER2-expressing EOC into the clinical trial stage.